Therapeutic Indication

Asthma and COPD

In the treatment and prophylaxis of bronchospasm and inflammation associateed with asthma, chronic bronchitis and emphysema. Also indicated in adults for the treatment of cardiac asthma and left ventricular or congestive cardiac failure.

Pharmaceutical Form

Appearance

Pale yellow, film- coated, modified- release tablet with the Napp logo on one side and SA on the other

Health Insurance Code

BC18279100

License

衛署藥輸字第018279號

Qualitative and Quantitative Composition

Tablet containing 225mg of aminophylline hydrate Ph Eur.

Dose and Administration

Oral: A controlled- released tablet are not to be chewed or crushed, because that may lead to a rapid release of aminophylline with the potenial of toxicity. The tablet may be halved, if required during the initial week of therapy or for dose titration.

Children: The maintenance dose (expressed as mg aminophyyline) is 12mg/kg twice daily adjusted to the nearest 125mg. It is recommended that half the maintenance dose be given for the first week of therapy if the patient has not previously been receiving xanthine preparations.
Some children with chronic asthma require and tolerate much higher doses (13-20mg/kg twice daily). Lower doses (based on the usual adult dose) may be required for adolescents. Not recommended for Children under 3 years of age.

Adults: The usual dose is two PHYLLCONTIN CONTINUS tablet 225mg twice- daily following an intial week of therapy on one tablet twice daily.

The elderly: The dose should be adjusted following the response to the initital week of therapy on one tablet twice - daily.